JENKEM(SH:688356)2024-10-30 10:58Financial Performance - The company's operating revenue for Q3 2024 was ¥57,139,662.87, a decrease of 21.56% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥4,708,953.10, reflecting a significant decline of 85.38% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,003,504.57, down 86.44% from the previous year[2]. - The basic earnings per share for Q3 2024 was ¥0.08, a decrease of 85.19% compared to the same period last year[4]. - Total operating revenue for the first three quarters of 2024 was CNY 185,726,750.89, a decrease of 24% compared to CNY 244,273,054.82 in the same period of 2023[14]. - Operating profit for the first three quarters of 2024 was CNY 35,545,460.69, down from CNY 111,624,195.90 in 2023, reflecting a decline of approximately 68%[14]. - Net profit attributable to shareholders for the first three quarters of 2024 was CNY 32,653,746.12, a significant decrease of 68% compared to CNY 100,477,028.44 in 2023[15]. Research and Development - The total R&D investment for Q3 2024 was ¥18,083,428.28, representing an increase of 52.57% compared to the same period last year[4]. - R&D expenses accounted for 31.65% of operating revenue in Q3 2024, an increase of 15.38 percentage points year-over-year[4]. - The company reported an increase in R&D expenses by RMB 5.99 million, with outsourced R&D costs rising by RMB 9.32 million due to ongoing major R&D projects[10]. - Research and development expenses increased to CNY 46,031,518.11 in 2024, up from CNY 40,042,178.37 in 2023, representing a rise of approximately 15%[14]. - The clinical trial for the drug JK1201I for small cell lung cancer has progressed to Phase III, with the first subject enrolled by September 30, 2024[10]. - The company maintains confidence in the future development of PEG materials and their market prospects, actively supporting various innovative technology platforms[10]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥65,754,910.47, down 45.18% year-over-year[2]. - As of September 30, 2024, cash and cash equivalents amounted to RMB 129.16 million, compared to RMB 110.86 million at the end of 2023[11]. - Cash flow from operating activities for the first three quarters of 2024 was CNY 65,754,910.47, down 45% from CNY 119,946,397.91 in 2023[16]. - Total assets at the end of Q3 2024 were ¥1,340,971,881.80, a slight decrease of 0.34% from the end of the previous year[4]. - The company's total equity attributable to shareholders was CNY 1,267,366,381.93 as of Q3 2024, down from CNY 1,280,130,607.35 in Q3 2023[12]. - The ending balance of cash and cash equivalents rose to $129,161,234.54 from $174,105,765.51, indicating a decrease of approximately 26.0%[17]. Shareholder Information - The company reported non-recurring gains of ¥705,448.53 for Q3 2024, primarily from government subsidies and other income[5]. - The company repurchased a total of 147,914 shares, accounting for 0.244% of the total share capital, with a total expenditure of RMB 10.50 million[10]. - The basic earnings per share for the first three quarters of 2024 was CNY 0.54, a decrease from CNY 1.67 in the same period of 2023[15]. Liabilities and Financing - Total liabilities increased to CNY 73,605,499.87 in Q3 2024, compared to CNY 65,418,354.97 in Q3 2023, marking an increase of approximately 12%[12]. - Total cash inflow from financing activities was $6,381,248.00, down from $17,722,351.40, representing a decline of about 64.0%[17]. - The net cash flow from financing activities was -$46,951,281.02, worsening from -$41,397,765.91 in the previous period[17]. Future Outlook - The company is in a performance transformation phase, expecting stable sales of medical-grade polyethylene glycol materials, with potential slight growth in international sales[10]. - The company is implementing new accounting standards starting in 2024, which may affect future financial reporting[18].